Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,804 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study.
Eyre TA, Schuh A, Wierda WG, Brown JR, Ghia P, Pagel JM, Furman RR, Cheung J, Hamdy A, Izumi R, Patel P, Wang MH, Xu Y, Byrd JC, Hillmen P. Eyre TA, et al. Among authors: cheung j. Lancet Haematol. 2021 Dec;8(12):e912-e921. doi: 10.1016/S2352-3026(21)00305-7. Epub 2021 Nov 1. Lancet Haematol. 2021. PMID: 34735860 Free PMC article. Clinical Trial.
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, Ivan C, Morse J, Nelson M, Keating MJ, Wierda WG, Marszalek JR, Gandhi V. Patel VK, et al. Among authors: cheung jp. Leukemia. 2018 Apr;32(4):920-930. doi: 10.1038/leu.2017.321. Epub 2017 Nov 3. Leukemia. 2018. PMID: 29099493 Free PMC article.
Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib.
Alsadhan A, Cheung J, Gulrajani M, Gaglione EM, Nierman P, Hamdy A, Izumi R, Bibikova E, Patel P, Sun C, Covey T, Herman SEM, Wiestner A. Alsadhan A, et al. Among authors: cheung j. Clin Cancer Res. 2020 Jun 15;26(12):2800-2809. doi: 10.1158/1078-0432.CCR-19-3505. Epub 2020 Feb 13. Clin Cancer Res. 2020. PMID: 32054731 Free PMC article. Clinical Trial.
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Sun C, Nierman P, Kendall EK, Cheung J, Gulrajani M, Herman SEM, Pleyer C, Ahn IE, Stetler-Stevenson M, Yuan CM, Maric I, Gaglione EM, Harris HM, Pittaluga S, Wang MH, Patel P, Farooqui MZH, Izumi R, Hamdy A, Covey T, Wiestner A. Sun C, et al. Among authors: cheung j. Blood. 2020 Jul 2;136(1):93-105. doi: 10.1182/blood.2019003715. Blood. 2020. PMID: 32202637 Free PMC article. Clinical Trial.
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.
Collins GP, Clevenger TN, Burke KA, Yang B, MacDonald A, Cunningham D, Fox CP, Goy A, Gribben J, Nowakowski GS, Roschewski M, Vose JM, Vallurupalli A, Cheung J, Raymond A, Nuttall B, Stetson D, Dougherty BA, Schalkwijk S, Carnevalli LS, Willis B, Tao L, Harrington EA, Hamdy A, Izumi R, Pease JE, Frigault MM, Flinn I. Collins GP, et al. Among authors: cheung j. Leuk Lymphoma. 2021 Nov;62(11):2625-2636. doi: 10.1080/10428194.2021.1938027. Epub 2021 Jul 16. Leuk Lymphoma. 2021. PMID: 34269152 Free article. Clinical Trial.
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects.
Sharma S, Pepin X, Cheung J, Zheng L, Wei H, Townsley D, Han D, Majewski M, Ware JA, Mann J, Munugalavadla V, Sheridan L, Patel P, Gupta A, Tomkinson H. Sharma S, et al. Among authors: cheung j. Br J Clin Pharmacol. 2022 Oct;88(10):4573-4584. doi: 10.1111/bcp.15362. Epub 2022 May 25. Br J Clin Pharmacol. 2022. PMID: 35466438 Free article. Clinical Trial.
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia.
Bibikova E, Parsa S, Floren M, Law B, Clevenger T, Cheung J, De Jesus G, Burke K, Gulrajani M, Yamaguchi K, Do P, Dougherty B, Whitston D, Brock G, Munugalavadla V, Frigault MM, Hartmann TN, Byrd JC, Furman RR, Brown JR, Covey T, Mortlock A. Bibikova E, et al. Among authors: cheung j. Hematol Oncol. 2025 Jan;43(1):e70008. doi: 10.1002/hon.70008. Hematol Oncol. 2025. PMID: 39716442 Clinical Trial.
Role of PD-1 during effector CD8 T cell differentiation.
Ahn E, Araki K, Hashimoto M, Li W, Riley JL, Cheung J, Sharpe AH, Freeman GJ, Irving BA, Ahmed R. Ahn E, et al. Among authors: cheung j. Proc Natl Acad Sci U S A. 2018 May 1;115(18):4749-4754. doi: 10.1073/pnas.1718217115. Epub 2018 Apr 13. Proc Natl Acad Sci U S A. 2018. PMID: 29654146 Free PMC article.
1,804 results